Cardiovascular Changes in Patients During the Post-Covid

Abstract

The long-term impact of COVID-19 on cardiovascular health remains underexplored, despite emerging evidence suggesting persistent myocardial damage in post-infection patients. This study investigates cardiovascular changes observed in individuals who have recovered from COVID-19, focusing on left ventricular ejection fraction (LVEF), myocardial fibrosis, and biomarker levels.

While acute cardiovascular effects of COVID-19 are well-documented, there is a significant gap in understanding the chronic cardiovascular abnormalities that persist after recovery. The persistence of myocardial injury and inflammation in post-COVID patients has not been thoroughly studied, indicating a critical need for further research into long-term cardiovascular outcomes.

To address this gap, we evaluated a cohort of 100 post-COVID patients using echocardiography, cardiac MRI, and biomarker analysis. Key parameters assessed included LVEF, myocardial fibrosis, and levels of troponin and C-reactive protein (CRP). Data were analyzed to determine the prevalence of cardiovascular abnormalities and their correlation with clinical symptoms.

The study revealed that 30% of patients had a reduced LVEF, 25% exhibited myocardial fibrosis, and 15% had arrhythmias. Elevated levels of troponin and CRP were found in 40% of patients, indicating ongoing myocardial inflammation and injury. These findings highlight that cardiovascular abnormalities continue to affect a substantial proportion of COVID-19 survivors.

These results emphasize the necessity of incorporating routine cardiovascular assessments into post-COVID care protocols. Ongoing monitoring and targeted management are essential to mitigate long-term cardiovascular risks associated with COVID-19. Future research, particularly longitudinal studies, is crucial to explore the progression of these abnormalities and develop effective treatment strategies.